Succinate-Based Dietary Supplement for Menopausal Symptoms: A Pooled Analysis of Two Identical Randomized, Double-Blind, Placebo-Controlled Clinical Trials

Table 4

State-trait anxiety inventory results.

Anxiety	Time	Supplement n = 114	Placebo n = 113
SA (state anxiety)	Initial	−1.0 [−7.0, 7.0]	−3.0 [−10.0, 3.0]	0.0583
	30 days	−5.0 [−9.0, 1.0]	−2.0 [−7.0, −3.0]	0.0495
	60 days	−7.0 [−11.0, −3.0]	0.0 [−6.0, 4.0]	≤0.001
	90 days	−8.0 [−13.0, −4.0]	−1.0 [−7.0, −4.0]	≤0.001
		<0.05	<0.05
TA (trait anxiety)	Initial	14.0 [8.0, 22.0]	11.0 [7.0, 17.0]	0.0125
	30 days	10.0 [5.0, 15.0]	13.0 [8.0, 17.0]	0.0212
	60 days	7.0 [4.0, 10.0]	14.0 [9.0, 21.0]	≤0.001
	90 days	4.0 [1.0, 8.0]	16.0 [9.0, 20.0]	≤0.001
		<0.05	<0.05
АA (actual anxiety)	Initial	48.0 [37.0, 61.0]	42.0 [33.0, 53.0]	0.0146
	30 days	40.0 [32.0, 50.0]	44.0 [37.0, 55.0]	0.0110
	60 days	34.0 [28.0, 41.0]	48.0 [39.0, 57.0]	≤0.001
	90 days	30.0 [24.0, 38.0]	49.0 [36.0, 57.0]	≤0.001
		<0.05	<0.05

Indicated values are (Me [Q1, Q3]). : supplement versus placebo (Mann–Whitney test, t-test); : initial versus 90 days (Friedman test). Bold numbers indicate statistically significant values.